Juvenile idiopathic arthritis (JIA)*
HUMIRA is indicated for, in combination with methotrexate (MTX), reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients, 2 years of age and older who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). HUMIRA can be used as monotherapy in case of intolerance to MTX or when continued treatment with MTX is not appropriate. HUMIRA has not been studied in pediatric patients with polyarticular JIA aged less than 2 years.
Recommended dosing in polyarticular JIA (>2 years of age)1*†‡
EVERY OTHER WEEK (EOW) DOSING STARTING AT WEEK 0
Patients weighing 10 to <30 kg
Patients weighing ≥30 kg
A sodium citrate-free 20 mg pre-filled syringe (for pediatric use) is available for patients who need to administer a full 20 mg dose.1§
A 40 mg Pen and a 40 mg pre-filled syringe are also available for patients who need to administer a full 40 mg dose.1
Available data suggest that clinical response is usually achieved within 12 weeks of treatment. Efficacy and safety in patients who do not respond by Week 16 have not been established.1
* Patients may self-inject HUMIRA if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.1
† Please see the Product Monograph for complete dosing and administration instructions.
‡ A dose of 10 mg EOW can be considered for patients weighing 10 to <15 kg.1
§ Clinical significance has not been established.
Safety information
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma (HSTCL), serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic DMARDs or other TNF antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-866-8HUMIRA (1-866-848-6472).
* Polyarticular JIA
Reference:
1. HUMIRA Product Monograph. AbbVie Corporation.
CA-HUMR-210015A / OC23